Biodexa Announces Pricing of $10 Million Public Offering
December 18, 2025 Biodexa Announces Pricing of $10 Million Public Offering Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”),...
Brain
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator,...
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator,...
Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
On track for interim analysis in late January 2026 and topline final results November 2026SYDNEY, Dec. 18, 2025 (GLOBE NEWSWIRE)...
Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
On track for interim analysis in late January 2026 and topline final results November 2026SYDNEY, Dec. 18, 2025 (GLOBE NEWSWIRE)...
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine
Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to...
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine
Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to...
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for...
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for...
Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients
Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke severity, prior to treatment in...
CranioSense Awarded $5.5 Million in Federal Grants to Validate Noninvasive Neurotech
BOSTON, Dec. 17, 2025 /PRNewswire/ -- CranioSense, Inc., a neurotechnology company developing the world's first noninvasive intracranial pressure (ICP) diagnostic and...
Restart Life Announces Food Technology and Research Studies
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF)...
Restart Life Announces Food Technology and Research Studies
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF)...
Washington Research Foundation announces 2026 cohort of WRF Postdoctoral Fellows
12 early-career researchers will receive three years of support to carry out projects at the Institute for Systems Biology, University...
Insightec Announces Spin-Out of Lotus Neuro to Advance Focused Ultrasound Brain Therapies
Lotus Neuro builds on Insightec's groundbreaking focused ultrasound platform to accelerate next-generation brain therapies globally, with funding from Nexus NeuroTech...
Kara Ball Recognized with Bezos Courage & Civility Award by Jeff Bezos and Lauren Sánchez Bezos
$5 million grant to Understood.org honors Ball's leadership in helping students with learning and thinking differences receive access to STEM...
Bioptimus Unveils M-Optimus, a World Model for Biology
Revolutionary model represents a transformative step toward AI-powered virtual tissues, patient digital twins, and a new era of data-driven biomedical...
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated...
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated...
Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates
Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities...